A Multicenter, Parallel-group-comparison, Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation

Trial Profile

A Multicenter, Parallel-group-comparison, Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2016

At a glance

  • Drugs OPC 108459 (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 22 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 01 Mar 2016 Planned End Date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 01 Mar 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top